NASDAQ:BLRX - BIOLINERX LTD/S News Headlines

$0.35
+0.01 (+2.97 %)
(As of 06/19/2019 09:20 AM ET)
Today's Range
$0.3330
Now: $0.3468
$0.3481
50-Day Range
$0.31
MA: $0.36
$0.41
52-Week Range
$0.31
Now: $0.3468
$1.84
Volume560,241 shs
Average Volume519,697 shs
Market Capitalization$38.88 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58

Headlines

BIOLINERX LTD/S (NASDAQ BLRX) News Headlines

Source:
DateHeadline
BIOLINERX LTD/S (NASDAQ:BLRX) Receives Consensus Rating of "Buy" from BrokeragesBIOLINERX LTD/S (NASDAQ:BLRX) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - June 17 at 4:40 PM
BioLineRx to Present at the JMP Securities 2019 Life Sciences ConferenceBioLineRx to Present at the JMP Securities 2019 Life Sciences Conference
finance.yahoo.com - June 13 at 12:52 PM
Zacks: Brokerages Expect BIOLINERX LTD/S (NASDAQ:BLRX) Will Post Earnings of -$0.05 Per ShareZacks: Brokerages Expect BIOLINERX LTD/S (NASDAQ:BLRX) Will Post Earnings of -$0.05 Per Share
www.americanbankingnews.com - June 8 at 8:10 PM
BioLineRx (BLRX) Moves to Buy: Rationale Behind the UpgradeBioLineRx (BLRX) Moves to Buy: Rationale Behind the Upgrade
finance.yahoo.com - May 18 at 6:55 AM
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2019 Results - Earnings Call TranscriptBioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2019 Results - Earnings Call Transcript
seekingalpha.com - May 14 at 8:05 PM
BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate UpdateBioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update
finance.yahoo.com - May 14 at 8:35 AM
BioLineRx to Report First Quarter 2019 Results on May 14, 2019BioLineRx to Report First Quarter 2019 Results on May 14, 2019
finance.yahoo.com - May 7 at 7:05 PM
BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid TumorsBioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors
finance.yahoo.com - May 7 at 8:20 AM
Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019Biotech News, What Milestones and Catalysts Could Drive BioLineRx Shares in 2019
finance.yahoo.com - May 1 at 7:32 PM
BioLineRx Reports Year End 2018 Financial Results and Provides Corporate UpdateBioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - March 28 at 8:22 AM
BioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma PatientsBioLineRx Announces Successful Engraftment Data From Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients
finance.yahoo.com - March 27 at 8:20 AM
BioLineRx to Report Annual 2018 Results on March 28, 2019BioLineRx to Report Annual 2018 Results on March 28, 2019
finance.yahoo.com - March 21 at 8:44 AM
BioLineRx to Present at the 29th Annual Oppenheimer Healthcare ConferenceBioLineRx to Present at the 29th Annual Oppenheimer Healthcare Conference
finance.yahoo.com - March 14 at 8:22 AM
BioLineRx: With A Lot Of Cash In Hand And UndervaluedBioLineRx: With A Lot Of Cash In Hand And Undervalued
seekingalpha.com - February 8 at 8:14 AM
BioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and WarrantsBioLineRx Announces Closing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
finance.yahoo.com - February 7 at 6:46 PM
Mid-Morning Market Update: Markets Open Higher; Archer Daniels Midland Earnings Miss ViewsMid-Morning Market Update: Markets Open Higher; Archer Daniels Midland Earnings Miss Views
www.benzinga.com - February 6 at 8:18 AM
BioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and WarrantsBioLineRx Announces Pricing of $15.4 Million Underwritten Public Offering of its American Depositary Shares and Warrants
finance.yahoo.com - February 5 at 6:35 PM
BioLineRx Wins Orphan Drug Status for Cancer TreatmentBioLineRx Wins Orphan Drug Status for Cancer Treatment
www.baystreet.ca - February 5 at 6:28 AM
BioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and WarrantsBioLineRx Announces Proposed Underwritten Public Offering of its American Depositary Shares and Warrants
finance.yahoo.com - February 5 at 6:28 AM
BioLineRx to Present at the 2019 Biotech ShowcaseBioLineRx to Present at the 2019 Biotech Showcase
finance.yahoo.com - January 2 at 5:33 PM
BioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology CollaborationBioLineRx Announces Initiation of Triple Combination Arm of Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer Under Immuno-Oncology Collaboration
finance.yahoo.com - December 11 at 8:29 AM
BioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New YorkBioLineRx to Host Investor and Analyst Breakfast Meeting on December 11, 2018 in New York
finance.yahoo.com - December 6 at 8:19 AM
BioLineRx (BLRX) Receives FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134BioLineRx (BLRX) Receives FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
www.streetinsider.com - November 21 at 5:15 PM
BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134BioLineRx Announces Receipt of FDA Biological Product Designation for Novel Cancer Immunotherapy Candidate AGI-134
finance.yahoo.com - November 20 at 8:14 AM
Recent Analysis Shows BioLineRx, Interlink Electronics, IMV INC, PAR Technology, Hudson Global, and Identiv Market Influences — Renewed Outlook, Key Drivers of GrowthRecent Analysis Shows BioLineRx, Interlink Electronics, IMV INC, PAR Technology, Hudson Global, and Identiv Market Influences — Renewed Outlook, Key Drivers of Growth
finance.yahoo.com - November 16 at 8:12 AM
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q3 2018 Results - Earnings Call TranscriptBioLineRx Ltd. (BLRX) CEO Phil Serlin on Q3 2018 Results - Earnings Call Transcript
seekingalpha.com - November 8 at 5:44 PM
BioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial UpdateBioLineRx Reports Significant Progress Across Oncology Programs and Provides Third Quarter Financial Update
finance.yahoo.com - November 8 at 8:14 AM
BioLineRx to Report Third Quarter 2018 Results on November 8, 2018BioLineRx to Report Third Quarter 2018 Results on November 8, 2018
finance.yahoo.com - November 1 at 6:11 PM
BioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 CongressBioLineRx Presents Top-line Results from Phase 2a COMBAT/KEYNOTE-202 Study in Pancreatic Cancer at ESMO 2018 Congress
finance.yahoo.com - October 19 at 8:20 AM
BioLineRx, High Potential Near Term Catalysts, Analysts Review and TargetBioLineRx, High Potential Near Term Catalysts, Analysts Review and Target
finance.yahoo.com - October 17 at 8:19 AM
Can The Uptrend Continue for BioLineRx (BLRX)?Can The Uptrend Continue for BioLineRx (BLRX)?
finance.yahoo.com - October 8 at 4:51 PM
Top Analysts Have 5 New Red-Hot Stocks Trading Under $10 to Buy NowTop Analysts Have 5 New Red-Hot Stocks Trading Under $10 to Buy Now
www.msn.com - October 6 at 8:12 AM
VTVT Abuzz, TRVN Faces FDA Panel Next Week, BLRX Awaits Data In Oct.VTVT Abuzz, TRVN Faces FDA Panel Next Week, BLRX Awaits Data In Oct.
www.nasdaq.com - October 4 at 8:12 AM
BioLineRx (BLRX) Reports Agreement with Biokine Therapeutics to Boost Stake in BL-8040 to 80% (from 60%)BioLineRx (BLRX) Reports Agreement with Biokine Therapeutics to Boost Stake in BL-8040 to 80% (from 60%)
www.streetinsider.com - October 4 at 8:12 AM
BioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology IndicationsBioLineRx Increases Stake in BL-8040, its Lead Oncology Platform in Late Stage Development for Multiple Oncology Indications
finance.yahoo.com - October 3 at 8:18 AM
BioLineRx (BLRX) Continue to Surge Higher?BioLineRx (BLRX) Continue to Surge Higher?
finance.yahoo.com - September 21 at 4:57 PM
Todays Research Reports on Trending Tickers: ACADIA Pharmaceuticals and BioLineRxToday's Research Reports on Trending Tickers: ACADIA Pharmaceuticals and BioLineRx
finance.yahoo.com - September 21 at 8:18 AM
BioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New YorkBioLineRx to Present at 20th Annual Rodman & Renshaw Global Investment Conference in New York
finance.yahoo.com - August 30 at 8:23 AM
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q2 2018 Results - Earnings Call TranscriptBioLineRx Ltd. (BLRX) CEO Phil Serlin on Q2 2018 Results - Earnings Call Transcript
seekingalpha.com - August 13 at 5:53 PM
BioLineRx Reports Second Quarter 2018 Financial ResultsBioLineRx Reports Second Quarter 2018 Financial Results
finance.yahoo.com - August 13 at 8:10 AM
BioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell MobilizationBioLineRx Announces Positive Results of Lead-in Period for Phase 3 GENESIS Trial in Stem-Cell Mobilization
finance.yahoo.com - August 7 at 8:13 AM
BioLineRx to Report Second Quarter 2018 Results on August 13, 2018BioLineRx to Report Second Quarter 2018 Results on August 13, 2018
finance.yahoo.com - August 6 at 8:05 AM
BioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid TumorsBioLineRx Initiates Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors
finance.yahoo.com - August 1 at 8:14 AM
BioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic CancerBioLineRx Announces Expansion of Immuno-Oncology Collaboration in Pancreatic Cancer
finance.yahoo.com - July 30 at 8:15 AM
BioLineRx Sees Hammer Chart Pattern: Time to Buy?BioLineRx Sees Hammer Chart Pattern: Time to Buy?
www.zacks.com - June 29 at 6:44 AM
BioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML PatientsBioLineRx Presents New Overall Survival Data From Phase 2a Study for BL-8040 in r/r AML Patients
finance.yahoo.com - June 18 at 8:39 AM
BioLineRx to Participate at JMP Securities 2018 Life Sciences ConferenceBioLineRx to Participate at JMP Securities 2018 Life Sciences Conference
finance.yahoo.com - June 13 at 8:17 AM
BioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2018 Results - Earnings Call TranscriptBioLineRx Ltd. (BLRX) CEO Phil Serlin on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 22 at 5:12 PM
Biolinerx reports Q1 resultBiolinerx reports Q1 result
seekingalpha.com - May 22 at 8:15 AM
Form 6-K BioLineRx Ltd. For: May 22Form 6-K BioLineRx Ltd. For: May 22
www.streetinsider.com - May 22 at 8:15 AM
This page was last updated on 6/19/2019 by MarketBeat.com Staff

Featured Article: What are Bollinger Bands?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel